Addressing the insulin secretion defect: A logical first-line approach

Metabolism: Clinical and Experimental

Volumn 49, Issue 10 SUPPL. 2, 2000, Pages 12-16

  Gerich, J E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

CELL FUNCTION; CONFERENCE PAPER; DIABETOGENESIS; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; TISSUE SPECIFICITY;

EID: 0033787539     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2000.17824     Document Type: Conference Paper

References (57)

1. Genetic and environmental determinants of noninsulin dependent diabetes mellitus (NIDDM)
2. The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity
3. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus
4. In vivo action and muscle glycogen synthase activity in type II (noninsulin dependent) diabetes mellitus: Effects of diet treatment
5. Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year
6. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus: Effect of weight loss
7. Maturity-onset diabetes of the young (MODY)
8. Insulin resistance: Lessons from patients with mutations in the insulin-receptor gene
9. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)
10. Genetics and the metabolic syndrome
11. Noninsulin-dependent diabetes mellitus - A genetically programmed failure of the beta cell to compensate for insulin resistance
12. Pathophysiology of insulin resistance in human disease
13. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: Prospective studies of Pima Indians
14. Physiologic evaluation of factors controlling glucose tolerance in man: Measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose
15. Different factors regulate glucose tolerance and insulinemia in NGT and IGT subjects
16. U.K. prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes - A progressive disease
17. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: The 10-year follow-up of the Belfast Diet Study
18. The cell physiology of biphasic insulin secretion
19. Is insulin resistance the principal cause of type 2 diabetes?
20. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose
21. Pulsatile secretion of fuel-regulatory hormones
22. Efficacy of pulsalile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans
23. Effects of pulsatile delivery of insulin and glucagon in humans
24. Decreased insulin secretory capacity and normal pancreatic B-cell glucose sensitivity in nonobese patients with NIDDM
25. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance
26. Elevated plasma glucose 2h postchallenge predicts defects in B-cell function
27. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM
28. Impaired pulsatile secretion of insulin in relatives of patients with noninsulin-dependent diabetes
29. Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes
30. Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM
31. Diminished β-cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
32. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy
33. Pharmacologic therapy for type 2 diabetes mellitus
34. Insulin secretogogues: Old and new
35. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects
36. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: Role of initial continuous subcutaneous insulin infusion-induced normoglycemia
37. Fasting hyperglycemia in noninsulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake
38. Is muscle the major site of insulin resistance in type 2 (noninsulin-dependent) diabetes mellitus?
39. Control of glycaemia
40. Effects of insulin on glucose turnover rates in vivo: Isotope dilution versus constant specific activity technique
41. Renal glucose production and utilization: New aspects in humans
42. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (Type II) diabetes mellitus
43. Relationship between the basal glucose concentration, glucose tolerance, and forearm glucose uptake in maturity-onset diabetes
44. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues
45. Effects of basal insulin supplementation on disposition of a mixed meal in obese patients with NIDDM
46. Contribution of abnormal muscle and liver glucose metabolism in postprandial hyperglycemia in noninsulin-dependent diabetes mellitus
47. Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus
48. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus
49. Contribution of impaired muscle glucose clearance to reduced postabsorptive systemic glucose clearance in NIDDM
50. Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load
51. The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man
52. The disposal of an oral glucose load in patients with noninsulin-dependent diabetes
53. 3H]-glucose
54. Oral hypoglycemic agents
55. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
56. Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM): Results of the feasibility trial
57. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance